1 active not recruiting, 1 completed, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
Follow Maximum Tolerated Dose: new trials by email Literature Review of Maximum Tolerated Dose trials Research Report on Maximum Tolerated Dose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml) - Chemo-refractory Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | AIO-Studien-gGmbH | 11 | 2022-02-17 | 2025-10-03 |
| Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC 350 mg leronlimab, 525 mg leronlimab, 700 mg leronlimab - Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | Terminated | CytoDyn, Inc. | 10 | 2019-04-22 | 2025-09-09 |
| Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma MLN9708, Dexamethasone, Bendamustine (multiple dose levels) - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Parameswaran Hari | 38 | 2015-10-09 | 2020-10-22 |
Colorectal Neoplasms (1) · Multiple Myeloma (1) · Triple Negative Breast Neoplasms (1)
AIO-Studien-gGmbH (1) · CytoDyn, Inc. (1) · Parameswaran Hari (1)
United States (2) · Germany (1)
Jacob Lalezari, MD (1) · Parameswaran Hari, MD, MRCP, MS (1) · Thomas Seufferlein, Prof.Dr.med. (1)